<!DOCTYPE html> <html lang="en">
Survodutide for Weight Loss: What the Clinical Trials Actually Show (2026)
⚡ Quick Answer
What is Survodutide? Survodutide (BI 456906) is a once-weekly injectable dual agonist developed by Boehringer Ingelheim and Zealand Pharma that activates both GLP-1 and glucagon receptors — skipping the GIP component used by Tirzepatide in favour of more powerful glucagon-driven fat oxidation.
Key results: Phase 2 trials showed 18.7% body weight loss at 46 weeks, with exceptional efficacy in reducing liver fat (NASH/NAFLD) — outperforming GLP-1-only peptides in liver-specific outcomes.
FDA Status: Phase 3 trials ongoing (2024–2026). Not yet approved.
What Is Survodutide?
Survodutide (development code BI 456906) is co-developed by Boehringer Ingelheim and Zealand Pharma. It is a GLP-1/glucagon dual agonist — a different dual combination than Tirzepatide (which uses GLP-1 + GIP). By pairing GLP-1 with glucagon receptor activation instead of GIP, Survodutide takes a distinct metabolic approach that may offer advantages for specific populations, particularly those with nonalcoholic steatohepatitis (NASH) or significant liver fat accumulation.
Survodutide vs Tirzepatide: Different Dual Combos
Both are dual agonists, but they pair GLP-1 with different second receptors. Tirzepatide uses GIP (improves insulin response and amplifies GLP-1 appetite effects). Survodutide uses glucagon (directly burns liver fat and raises energy expenditure). Neither is strictly “better” — they excel in different contexts, with Survodutide having a particular edge in metabolic liver disease.
How Survodutide Works
| Receptor | Effect | Fat Loss Contribution |
|---|---|---|
| GLP-1R | Appetite suppression, slowed gastric emptying, insulin release | Reduced caloric intake; caloric deficit creation |
| GCGR (Glucagon) | Hepatic fat oxidation, thermogenesis, increased energy expenditure | Direct liver fat burning; elevated metabolic rate; visceral fat reduction |
The glucagon component is especially significant for hepatic (liver) fat. Glucagon receptor activation in the liver directly triggers fat oxidation — the burning of stored liver triglycerides for energy. This makes Survodutide one of the most promising treatments for NAFLD and NASH currently in trials, outperforming GLP-1-only peptides in liver-specific outcomes.
Clinical Trial Results
Phase 2 Obesity Trial
The primary Phase 2 trial enrolled adults with obesity across four dose cohorts over 46 weeks. Key findings:
| Dose | Weight Loss | Liver Fat Reduction | Key Metabolic Improvements |
|---|---|---|---|
| 2.4mg weekly | 13.2% | ~40% reduction in liver fat | Improved fasting glucose, triglycerides |
| 4.8mg weekly | 18.7% | ~55% reduction in liver fat | Significant HbA1c reduction; LDL improvement |
| Placebo | 1.8% | Minimal | No significant change |
NASH/NAFLD Trial Results
In a dedicated NASH population trial, Survodutide produced 83% NASH resolution rate at the highest dose — one of the strongest results ever recorded in a liver disease peptide trial, outperforming both Semaglutide and Tirzepatide in liver-specific outcomes.
Survodutide vs Semaglutide vs Tirzepatide
| Compound | Mechanism | Weight Loss | Liver Fat Reduction | Best For |
|---|---|---|---|---|
| Survodutide | GLP-1 + Glucagon | 18.7% | ⭐⭐⭐⭐⭐ Exceptional | NASH/NAFLD, visceral fat, metabolic syndrome |
| Tirzepatide | GLP-1 + GIP | 22.5% | ⭐⭐⭐⭐ Very Good | Maximum overall weight loss, T2D |
| Semaglutide | GLP-1 | 17.3% | ⭐⭐⭐ Good | Proven safety, CV risk reduction, beginners |
Survodutide for Liver Disease (NAFLD/NASH)
This is where Survodutide may ultimately prove most valuable. Glucagon receptor activation drives hepatic beta-oxidation — the metabolic process by which the liver breaks down its own stored fat for energy. Combined with GLP-1’s improvements in insulin sensitivity (which reduces new fat delivery to the liver), Survodutide addresses liver fat accumulation from both directions simultaneously.
For patients with NAFLD or NASH, Survodutide may become the preferred first-line peptide therapeutic — not necessarily because it produces the most weight loss, but because its liver-specific mechanism addresses the underlying pathology more directly than GLP-1-only approaches.
Side Effects & Safety
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | 40–50% | Most common; typically resolves within 4–6 weeks |
| Vomiting | 18–22% | Dose-dependent; manageable with slow escalation |
| Diarrhea | 18–20% | Similar to other GLP-1 compounds |
| Elevated heart rate | 8–12% | Glucagon-mediated; mild (+3–6 bpm); monitor in CV disease |
| Decreased appetite | Very common | Therapeutic effect; ensure adequate protein intake |
Current Status & Availability
Survodutide is in active Phase 3 trials across obesity and NASH indications as of 2026. It is not FDA-approved. Research-grade Survodutide is available through select suppliers for non-human research purposes. Commercial approval is anticipated in 2027 if Phase 3 results replicate Phase 2 findings.
Frequently Asked Questions
Is Survodutide better than Tirzepatide?
For overall weight loss, Tirzepatide still leads (22.5% vs 18.7%). For liver fat reduction and NASH resolution, Survodutide outperforms. The better choice depends on the individual’s primary goal and metabolic profile.
Can Survodutide treat fatty liver disease?
Phase 2 data is extremely promising — 83% NASH resolution in the highest dose group, and 55% liver fat reduction. Phase 3 NASH-specific trials are ongoing. This may become Survodutide’s primary approved indication.
When will Survodutide be available by prescription?
Phase 3 results are expected in 2026–2027. FDA approval could follow in 2027–2028 if results are positive, with NASH potentially being the first approved indication given the high unmet need.
📚 References
- Boehringer Ingelheim. “Survodutide Phase 2 Obesity Results.” NEJM Evidence, 2024.
- Zealand Pharma. “BI 456906 NASH Phase 2 Trial.” ClinicalTrials.gov, 2024.
- Ambery P. et al. “MEDI0382, a GLP-1 and glucagon receptor dual agonist.” The Lancet, 2018.
- Broomfield A. et al. “Glucagon receptor agonism in NAFLD.” Journal of Hepatology, 2022.
Explore Today’s Best Available Options
While Survodutide awaits approval, these are the most effective peptides available now:
Tirzepatide Semaglutide Tesamorelin All Weight Loss Peptides →